Taysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week High – Time to Buy?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $5.54 and last traded at $5.4440, with a volume of 3382537 shares changing hands. The stock had previously closed at $5.05.

Analyst Ratings Changes

TSHA has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a research report on Friday, November 14th. Chardan Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. JMP Securities set a $8.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday. Finally, UBS Group set a $11.00 price objective on Taysha Gene Therapies in a research note on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Taysha Gene Therapies has an average rating of “Moderate Buy” and an average price target of $10.42.

Taysha Gene Therapies Stock Up 4.7%

The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. The company has a 50 day simple moving average of $4.66 and a two-hundred day simple moving average of $3.43. The firm has a market capitalization of $1.52 billion, a P/E ratio of -16.85 and a beta of 1.06.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. On average, equities analysts predict that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Insider Activity at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 260,047 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the transaction, the insider directly owned 1,006,439 shares in the company, valued at $4,539,039.89. This trade represents a 20.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 3.78% of the company’s stock.

Hedge Funds Weigh In On Taysha Gene Therapies

Large investors have recently bought and sold shares of the business. Jefferies Financial Group Inc. boosted its holdings in Taysha Gene Therapies by 4,105.3% in the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock worth $23,825,000 after acquiring an additional 10,068,479 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Taysha Gene Therapies in the 2nd quarter worth approximately $11,178,000. Barclays PLC grew its position in Taysha Gene Therapies by 1,042.8% during the 3rd quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock worth $16,834,000 after purchasing an additional 4,697,611 shares during the last quarter. MPM Bioimpact LLC acquired a new position in Taysha Gene Therapies during the 2nd quarter valued at approximately $6,823,000. Finally, Vestal Point Capital LP raised its holdings in shares of Taysha Gene Therapies by 83.3% in the third quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock worth $17,985,000 after buying an additional 2,500,000 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.